| Předmět: |
|
| Zdroj: |
Personalized Medicine in Oncology; Nov2013, Vol. 2 Issue 7, p389-395, 7p |
| Abstrakt: |
The article discusses information from the European Hematology Association (EHA) 2013 congress. The adenosine triphosphate analog imatinib selectively inhibits the enhanced tyrosine activity of the fusion gene BCR-ABL1 oncoprotein. The second-generation oral tyrosine kinase inibitor (TKI) nilotinib is significantly more potent than imatinib. The estimated probability of overall, progression-free, and failure-free survival in phase 2 GIMEMA CML0307 study in nilotinib treatment is 97% at 5 years. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
